FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886959094> ?p ?o ?g. }

• W2886959094 endingPage "723" @default.
• W2886959094 startingPage "719" @default.
• W2886959094 abstract "Management of micro-organisms harbouring AmpC β-lactamases remains challenging. Carbapenems are often considered first-line agents. Due to growing concern regarding carbapenem-resistant Enterobacteriaceae, integrating non-carbapenem treatment strategies is being explored for these pathogens. The primary objective of this study was to evaluate clinical outcomes in patients with bacteraemia secondary to AmpC-producing organisms treated with cefepime or piperacillin/tazobactam (TZP). A retrospective study of adult patients receiving cefepime or TZP for the treatment of AmpC -producing organisms with positive cefoxitin screen (i.e. Citrobacter, Enterobacter or Serratia spp. along with cefoxitin resistance) isolated from blood cultures was conducted. The primary endpoint was clinical cure at end of therapy (EOT). Secondary endpoints included microbiological eradication, frequency of susceptibility changes following treatment, and 7- and 30-day all-cause mortality. Clinical cure at EOT was 87.1%, with 93.2% of patients achieving microbiological eradication. The 7- and 30-day mortality rates were 3.8% and 10.6%, respectively. Organism susceptibility was exceptionally high, with minimum inhibitory concentrations (MICs) of ≤2 μg/mL in 90% of patients treated with cefepime (n = 108). Selection for resistance to third-generation cephalosporins or primary antimicrobial therapy was infrequent at 6.1% (8/132). In conclusion, use of cefepime or TZP for management of AmpC bloodstream infections was associated with clinical and microbiological cure with infrequent selection for resistance." @default.
• W2886959094 created "2018-08-22" @default.
• W2886959094 creator A5027796696 @default.
• W2886959094 creator A5041712605 @default.
• W2886959094 creator A5051367948 @default.
• W2886959094 creator A5052243109 @default.
• W2886959094 creator A5081264628 @default.
• W2886959094 creator A5089805828 @default.
• W2886959094 creator A5091563651 @default.
• W2886959094 date "2018-11-01" @default.
• W2886959094 modified "2023-10-01" @default.
• W2886959094 title "Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms" @default.
• W2886959094 cites W1967624732 @default.
• W2886959094 cites W2008553807 @default.
• W2886959094 cites W2041215841 @default.
• W2886959094 cites W2072321013 @default.
• W2886959094 cites W2083574963 @default.
• W2886959094 cites W2099303284 @default.
• W2886959094 cites W2101382361 @default.
• W2886959094 cites W2125863771 @default.
• W2886959094 cites W2135790423 @default.
• W2886959094 cites W2147778708 @default.
• W2886959094 cites W2166660180 @default.
• W2886959094 cites W2247218579 @default.
• W2886959094 cites W2579462991 @default.
• W2886959094 cites W2600757231 @default.
• W2886959094 cites W4230357700 @default.
• W2886959094 doi "https://doi.org/10.1016/j.ijantimicag.2018.08.007" @default.
• W2886959094 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30125680" @default.
• W2886959094 hasPublicationYear "2018" @default.
• W2886959094 type Work @default.
• W2886959094 sameAs 2886959094 @default.
• W2886959094 citedByCount "13" @default.
• W2886959094 countsByYear W28869590942019 @default.
• W2886959094 countsByYear W28869590942020 @default.
• W2886959094 countsByYear W28869590942021 @default.
• W2886959094 countsByYear W28869590942022 @default.
• W2886959094 countsByYear W28869590942023 @default.
• W2886959094 crossrefType "journal-article" @default.
• W2886959094 hasAuthorship W2886959094A5027796696 @default.
• W2886959094 hasAuthorship W2886959094A5041712605 @default.
• W2886959094 hasAuthorship W2886959094A5051367948 @default.
• W2886959094 hasAuthorship W2886959094A5052243109 @default.
• W2886959094 hasAuthorship W2886959094A5081264628 @default.
• W2886959094 hasAuthorship W2886959094A5089805828 @default.
• W2886959094 hasAuthorship W2886959094A5091563651 @default.
• W2886959094 hasConcept C104317684 @default.
• W2886959094 hasConcept C126322002 @default.
• W2886959094 hasConcept C177713679 @default.
• W2886959094 hasConcept C203092338 @default.
• W2886959094 hasConcept C2775945818 @default.
• W2886959094 hasConcept C2776124114 @default.
• W2886959094 hasConcept C2776685102 @default.
• W2886959094 hasConcept C2777050379 @default.
• W2886959094 hasConcept C2777637488 @default.
• W2886959094 hasConcept C2777858937 @default.
• W2886959094 hasConcept C2778193466 @default.
• W2886959094 hasConcept C2778266534 @default.
• W2886959094 hasConcept C2778983983 @default.
• W2886959094 hasConcept C2779443120 @default.
• W2886959094 hasConcept C2779489039 @default.
• W2886959094 hasConcept C2779631663 @default.
• W2886959094 hasConcept C4937899 @default.
• W2886959094 hasConcept C501593827 @default.
• W2886959094 hasConcept C523546767 @default.
• W2886959094 hasConcept C535046627 @default.
• W2886959094 hasConcept C54355233 @default.
• W2886959094 hasConcept C547475151 @default.
• W2886959094 hasConcept C55493867 @default.
• W2886959094 hasConcept C64778159 @default.
• W2886959094 hasConcept C71924100 @default.
• W2886959094 hasConcept C86803240 @default.
• W2886959094 hasConcept C89423630 @default.
• W2886959094 hasConcept C94665300 @default.
• W2886959094 hasConceptScore W2886959094C104317684 @default.
• W2886959094 hasConceptScore W2886959094C126322002 @default.
• W2886959094 hasConceptScore W2886959094C177713679 @default.
• W2886959094 hasConceptScore W2886959094C203092338 @default.
• W2886959094 hasConceptScore W2886959094C2775945818 @default.
• W2886959094 hasConceptScore W2886959094C2776124114 @default.
• W2886959094 hasConceptScore W2886959094C2776685102 @default.
• W2886959094 hasConceptScore W2886959094C2777050379 @default.
• W2886959094 hasConceptScore W2886959094C2777637488 @default.
• W2886959094 hasConceptScore W2886959094C2777858937 @default.
• W2886959094 hasConceptScore W2886959094C2778193466 @default.
• W2886959094 hasConceptScore W2886959094C2778266534 @default.
• W2886959094 hasConceptScore W2886959094C2778983983 @default.
• W2886959094 hasConceptScore W2886959094C2779443120 @default.
• W2886959094 hasConceptScore W2886959094C2779489039 @default.
• W2886959094 hasConceptScore W2886959094C2779631663 @default.
• W2886959094 hasConceptScore W2886959094C4937899 @default.
• W2886959094 hasConceptScore W2886959094C501593827 @default.
• W2886959094 hasConceptScore W2886959094C523546767 @default.
• W2886959094 hasConceptScore W2886959094C535046627 @default.
• W2886959094 hasConceptScore W2886959094C54355233 @default.
• W2886959094 hasConceptScore W2886959094C547475151 @default.
• W2886959094 hasConceptScore W2886959094C55493867 @default.
• W2886959094 hasConceptScore W2886959094C64778159 @default.

• next